Ucb
UCB, or UCB S.A., is a global biopharmaceutical company headquartered in Belgium. Founded in 1928, UCB has established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapies for neurological and immunological disorders. With a strong presence in Europe and North America, UCB is dedicated to improving the lives of patients through its core products, including treatments for epilepsy, Parkinson's disease, and autoimmune conditions. The company is renowned for its commitment to research and development, which has led to significant milestones such as the launch of several groundbreaking therapies. UCB's unique approach combines advanced science with patient-centric solutions, positioning it as a key player in the global healthcare market. With a robust pipeline and a focus on unmet medical needs, UCB continues to make notable strides in the biopharmaceutical landscape.
DitchCarbon Score
How does Ucb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ucb's score of 80 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ucb's reported carbon emissions
In 2023, UCB reported total greenhouse gas emissions of approximately 63,165,000 kg CO2e, comprising 20,547,000 kg CO2e from Scope 1, 17,867,000 kg CO2e from Scope 2, and 63,165,000 kg CO2e from Scope 3 emissions. This reflects a commitment to reducing absolute Scope 1, 2, and 3 emissions by 38% by 2030 from a 2015 baseline. UCB also aims for 60% of its suppliers, based on emissions, to have science-based targets by 2025. Looking ahead, UCB has set ambitious long-term goals, including achieving net-zero emissions across its value chain by 2045. Near-term targets include a 73% reduction in Scope 1 and 2 emissions and a 48% reduction in Scope 3 emissions by 2030, both from a 2019 base year. These targets align with the Science Based Targets initiative (SBTi) and are consistent with limiting global warming to well below 2°C. UCB's proactive approach to sustainability underscores its commitment to addressing climate change and reducing its carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 34,733,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 31,367,000 | 00,000,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 0,000 |
| Scope 3 | - | - | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ucb is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
